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3 of the 4 documented patients with stiff patient syndrome have mutations at the 
interface of actin and tropomyosin and therefore could affect the equilibrium of the 
Ca2+-dependent switch of muscle. ACTA1 gene (skeletal actin) K326N was 
previously reported, and we recently found stiff patients with ΔE218 and ΔE224 
mutations in the TPM3 gene (Tpm3.12 protein). The atomic resolution structure of 
tropomyosin bound to actin in the ‘switched off’ state shows that tropomyosin makes 
contact with actin at only two points, one of which is a cluster of basic amino acids 
actin K326, K328 and R147.  Tropomyosin has a seven-fold repeated structure 
corresponding to seven actin-binding interactions.  We have demonstrated that two 
Tpm2.2 mutations, ΔE139 and E181K, and the actin K326N mutation destabilise the 
actin–tropomyosin interface. We predicted that equivalent charge loss mutations at 
EE 218–219, EE 224–224, or ED 257–258 would also destabilise the interaction with 
actin, leading to a partial switch-on of the muscle. This was investigated by 
determining the Ca2+-dependence of activation of motility in a single filament assay. 
Using the quantitative in vitro motility assay and skeletal muscle thin filaments 
containing recombinant mutant Tpm3.12, we found increased Ca2+-sensitivity in both 
ΔE224 and ΔE218 tropomyosin mutations. ΔE218 led to a 2.5-fold increase in Ca2+-
sensitivity (EC50 ratio ΔΕ218/WT = 0.40 ± 0.07, p = 0.004). ΔΕ224 also showed an 
increase in Ca2+-sensitivity by 2.2-fold (EC50 ratio ΔΕ224/WT for = 0.46 ± 0.09, p = 
0.0). It has been previously shown that there was a 2.5-fold increase in Ca2+-
sensitivity for K326N actin (EC50 ratio K326N/WT = 0.4 ± 0.05, p = 0.07) in thin 
filaments reconstituted with wild type or mutant actin from biopsy and native 
tropomyosin and troponin. Increased Ca2+-sensitivity indicates that both mutations 
cause a gain of function that was predicted from the structural analysis and that can 
account for the stiff patient syndrome. 
